Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
Raúl M. Luque(Instituto de Salud Carlos III), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Alberto Moreno-Carazo(Complejo Hospitalario de Jaén), Eva Venegas‐Moreno(Hospital Universitario Virgen del Rocío), Michael D. Culler(Ipsen (United States)), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Mônica R. Gadelha(Universidade Federal do Rio de Janeiro), Leandro Kasuki(Universidade Federal do Rio de Janeiro), Leonardo Vieira Neto(Hospital Universitário Clementino Fraga Filho), Rhonda D. Kineman(University of Illinois Chicago), Alfonso Soto‐Moreno(Instituto de Biomedicina de Sevilla), Giselle Fernandes Taboada(Universidade Federal Fluminense), Daniel Hormaechea‐Agulla(Baylor College of Medicine), María A. Gálvez(Hospital Universitario Reina Sofía), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition)
Cited by 91
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
|The Journal of Clinical Endocrinology & Metabolism|2014|394
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
|The Journal of Clinical Endocrinology & Metabolism|2019|363
Consensus on diagnosis and management of Cushing's disease: a guideline update
|White Rose Research Online (University of Leeds, The University of Sheffield, University of York)|2021|351